Patients with long COVID may exhibit persistent inflammation in the heart and lungs for up to 1 year following acute COVID-19 ...

Yale researchers have built a 3D-bioprinted synthetic aorta that they have successfully implanted into rats. This technology ...

It often starts with sudden, sharp chest pain that feels unlike anything you have experienced before. It might spread to your ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

MemorialCare offers advanced, minimally invasive heart treatments like TAVR & MitraClip as alternatives to open-heart surgery ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement ...

Severe tricuspid valve regurgitation is a serious heart condition. The development of tricuspid valve implants is still in ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

25). “At two years, transcatheter edge-to-edge repair (TEER) for the treatment of symptomatic, severe tricuspid regurgitation appears to be safe, significantly reduced symptom severity and decreased ...

Results showed that TAVR patients compared with SAVR patients had higher rates of mild-to-severe aortic regurgitation (24.5% vs. 6.3%, p<0.001), as well as a higher mean transaortic gradient (12.8 vs.